Target intelligence / Profile preview

Intestinal microbiota restoration

Molecular classification
Other
01

Overview

Intestinal microbiota restoration refers to therapeutic interventions, such as fecal microbiota transplantation and microbiota restoration therapies, designed to re-establish a healthy balance and diversity of the gut microbiome. It is primarily used to treat recurrent Clostridioides difficile infection, is under investigation for other gastrointestinal and immune-mediated diseases, and functions by introducing beneficial microbes to outcompete pathogens, restore metabolic and immune functions, and enable gut homeostasis. This field is evolving, with approaches ranging from whole-stool transplantation to defined bacterial consortia and targeted small molecules or phage therapy, but "intestinal microbiota restoration" is a therapeutic principle, not a molecular or protein drug target.

Other names
Microbiota restorationMicrobiota restoration therapyGut microbiota restorationFecal microbiota restorationMicrobiome restoration
02

Mechanism of action

Engraftment of beneficial microbial taxa to displace pathogenic microorganisms; Restoration of microbial diversity and functions; Inhibition of antibiotic-resistant organisms; Increase in beneficial metabolite production (e.g., short-chain fatty acids); Immune system modulation

03

Biological functions

Restoration of microbial diversityMaintenance of gut homeostasisImmune modulationEnhancement of intestinal barrier functionRegulation of microbial metabolism
04

Disease associations

Recurrent Clostridioides difficile infectionInflammatory bowel disease (IBD)Irritable bowel syndrome (IBS)Antibiotic-resistant infectionsPotential roles in allergic diseases (e.g., eczema)
05

Safety considerations

Risk of transmitting infectious agents (e.g., undetected pathogens in FMT)Unpredictable engraftment and efficacyPotential adverse immune responsesInsufficient long-term safety data for some interventions
06

Interacting drugs

Fecal microbiota transplantation (FMT)

6 more in the full profile.

07

Biomarkers

Microbial diversity indices (e.g., alpha diversity)Abundance of specific beneficial bacterial taxa (e.g., Lachnospiraceae, Lactobacillaceae)Metabolite levels (e.g., short-chain fatty acids such as butyrate, acetate, propionate)Reduction in antibiotic resistance genes

Beyond the preview

Go deeper on Intestinal microbiota restoration.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal microbiota restoration.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call